Methodological and conceptual considerations for examining the α-FAtE scoring in unresectable hepatocellular carcinoma

Methodological and conceptual considerations for examining the α-FAtE scoring in unresectable hepatocellular carcinoma

Saved in:

Bibliographic Details
Main Author:	Güner Akgüner
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-01-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/1/e010840.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice
by: V. V. Petkau, et al.
Published: (2022-12-01)

Liver Transplantation in the Treatment of Unresectable Hepatocellular Carcinoma in the Absence of Liver Cirrhosis
by: O. D. Olisov, et al.
Published: (2018-09-01)

Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib
by: Hideko Ohama, et al.
Published: (2025-01-01)

TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma
by: Wang W, et al.
Published: (2025-01-01)

Vena Cava Superior Syndrome Related to Right Heart Invasion of an Unresectable Hepatocellular Carcinoma
by: Geert Maleux, et al.
Published: (2016-01-01)

Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma
by: Zhaosong Xue, et al.
Published: (2025-02-01)

Prediction of Pathologic Response in Unresectable Hepatocellular Carcinoma After Downstaging with Locoregional and Systemic Combination Therapy
by: Yang C, et al.
Published: (2025-01-01)

Hypofractionated Stereotactic Radiotherapy after Transarterial Chemoembolisation Failure in an Unresectable Hepatocellular Carcinoma: A Case Presentation
by: Francesco Fiorica, et al.
Published: (2013-01-01)

Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma
by: Yonghua Bi, et al.
Published: (2022-01-01)

Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States
by: Finn RS, et al.
Published: (2025-02-01)

The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy
by: Tian He, et al.
Published: (2025-01-01)

PPARα suppresses growth of hepatocellular carcinoma in a high-fat diet context by reducing neutrophil extracellular trap release
by: Banglun Pan, et al.
Published: (2025-01-01)

The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
by: Wu Y, et al.
Published: (2025-02-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis
by: Lingling Zhao, et al.
Published: (2025-02-01)

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study
by: Hongjie Cai, et al.
Published: (2025-02-01)

Deep learning-based CT radiomics predicts prognosis of unresectable hepatocellular carcinoma treated with TACE-HAIC combined with PD-1 inhibitors and tyrosine kinase inhibitors
by: Linan Yin, et al.
Published: (2025-01-01)

Surgical resection versus thermal ablation after intra-arterial conversion therapy for unresectable hepatocellular carcinoma: a multicenter retrospective one as per the STROBE guidelines
by: Yusen Du, et al.
Published: (2024-12-01)

A New Risk Score Based on Lipid Indicators for Patients with Advanced Hepatocellular Carcinoma
by: Wei X, et al.
Published: (2025-01-01)

Hsp90α promotes lipogenesis by stabilizing FASN and promoting FASN transcription via LXRα in hepatocellular carcinoma
by: Zihao Deng, et al.
Published: (2025-01-01)

Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01)

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
by: Da Xu, et al.
Published: (2025-02-01)

A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy
by: Hiroyuki Iwasaki, et al.
Published: (2020-01-01)

The Fate of the Scientist, the Fate of Science
by: E. B. Rashkovsky
Published: (2012-06-01)

Serum chemerin level in patients with liver cirrhosis and primary and multifocal hepatocellular carcinoma with consideration of insulin level
by: Monika Pazgan-Simon, et al.
Published: (2024-10-01)

Locally Advanced and Unresectable Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiotherapy
by: Robert M. Samstein, et al.
Published: (2014-01-01)

To construct and validate a risk score model of angiogenesis-related genes to predict the prognosis of hepatocellular carcinoma
by: Duangui Gao, et al.
Published: (2025-02-01)

Hepatocellular carcinoma risk scores for non-viral liver disease: A systematic review and meta-analysis
by: Laura Burke, et al.
Published: (2025-01-01)

A new prognostic model for predicting overall survival and progression-free survival in unresectable hepatocellular carcinoma treated with the FOLFOX-HAIC regimen based on patient clinical characteristics and blood biomarkers
by: Qiuyao Zeng, et al.
Published: (2025-01-01)

Epidemiology of Hepatocellular Carcinoma
by: Mimi C Yu, et al.
Published: (2000-01-01)

Biomarkers for Hepatocellular Carcinoma
by: Tara Behne, et al.
Published: (2012-01-01)

Metabolic Alteration in Hepatocellular Carcinoma: Mechanism of Lipid Accumulation in Well-Differentiated Hepatocellular Carcinoma
by: Hideo Suzuki, et al.
Published: (2021-01-01)

Social Networking and the Family Business Performance: A Conceptual Consideration
by: Kenneth Chukwujioke Agbim
Published: (2019-01-01)

Targeted Therapy in Hepatocellular Carcinoma
by: Clarinda W. L. Chua, et al.
Published: (2011-01-01)

Hepatocellular Carcinoma to the Right Ventricle
by: George R. Marzouka, et al.
Published: (2014-01-01)

Hepatocellular carcinoma in a sheep
by: Zabid Yener, et al.

Prognostic Utility of Prechemoradiotherapy Albumin-to-Alkaline Phosphatase Ratio in Unresectable Locally Advanced Pancreatic Carcinoma Patients
by: Veysel Haksoyler, et al.
Published: (2021-01-01)

Fate of the banished /
by: Ocwinyo, Julius, 1960-
Published: (2008)

Measuring Impunity in Latin America: Conceptual and Methodological Challenges
by: Juan Antonio Le Clercq, et al.
Published: (2016-05-01)

The Lexicon of Argumentation for Argument Mining: methodological considerations
by: Patrick Saint Dizier
Published: (2020-12-01)